Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Yosra RiahiUniversité Paris-Saclay, Inserm, Physiopathogénèse et Traitement des Maladies du Foie, FHU Hepatinov, 91400 Orsay, France.ORCID 0009-0001-8210-166X
Sylvain PetitUniversité Paris-Saclay, CNRS, BioCIS, 91400 Orsay, France.
Manon BanetUniversité Paris-Saclay, Inserm, Physiopathogénèse et Traitement des Maladies du Foie, FHU Hepatinov, 91400 Orsay, France.ORCID 0009-0004-3042-4776
Thomas FalguièresUniversité Paris-Saclay, Inserm, Physiopathogénèse et Traitement des Maladies du Foie, FHU Hepatinov, 91400 Orsay, France.ORCID 0000-0003-2867-0500
Isabelle CallebautSorbonne Université, Muséum National d'Histoire Naturelle, CNRS, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie (IMPMC), 75005 Paris, France.ORCID 0000-0003-3124-887X
Delphine JosephUniversité Paris-Saclay, CNRS, BioCIS, 91400 Orsay, France.
Emmanuel GonzalesUniversité Paris-Saclay, Inserm, Physiopathogénèse et Traitement des Maladies du Foie, FHU Hepatinov, 91400 Orsay, France.ORCID 0000-0002-1546-3193
Emmanuel JacqueminUniversité Paris-Saclay, Inserm, Physiopathogénèse et Traitement des Maladies du Foie, FHU Hepatinov, 91400 Orsay, France.ORCID 0000-0002-7536-6272
Funding
Agence Nationale de la Recherche ANR-21-CE18-0030-01Association Maladies du Foie depuis l'Enfance, AMFE, Malakoff, France Not applicableAssociation pour la Recherche en Hépatologie Pédiatrique, CHU Bicêtre, France Not applicableFilière de santé des maladies rares du foie (FILFOIE), Paris, France Not applicableIpsen (France) Not applicableMinistère de l'Enseignement Supérieur, de la Recherche et de l'Innovation Français Not applicable
6 · The paper itself
Abstract
Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a severe hepatocellular cholestasis due to biallelic variations in the
Indexed as
ATP Binding Cassette Transporter, Subfamily B, Member 11Cholestasis, IntrahepaticMutation, MissenseAnimalsDogsHumansPhenylbutyratesProtein Transport4-phenylbutyric acidABCB11 protein, humanATP Binding Cassette Transporter, Subfamily B, Member 11Phenylbutyrates4-phenylbutyrateABC transporterBSEPmissense variationpharmacological correctors
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Correction of a Traffic-Defective Missense ABCB11 Variant Responsible for Progressive Familial Intrahepatic Cholestasis Type 2. · full record | OpenQuestion